Detail of "27470-51-5"

CAS Number:
27470-51-5
Name:
Butanedioic acid,1-[(4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl] ester
Superlist Name:
Suxibuzone
Molecular Structure:
Formula:
C24H26 N2 O6
Molecular Weight:
438.52
Synonyms:
Butanedioicacid, mono[(4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl] ester (9CI);Succinic acid, monoester with4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (8CI);3,5-Pyrazolidinedione, 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-, hydrogensuccinate (ester) (8CI); 4-Hydroxymethylbutazolidine hemisuccinate; AE 17;Calibene; Danilon; Flogos; Solurol; Suxibutazone; Suxibuzone
Hazard Symbols:
Risk Codes:
20/21/22
Safety:
Poison by ingestion and intravenous routes. Moderately toxic by subcutaneous route. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NO_x. Details

Supplier Location
Supplier Location
- China (Mainland)(2)
Business Type
Business Type
- Lab/Research institutions(1)
- Manufacturers(0)
- Trading Company(1)
Certificates
Certificates
- ISO (0)
- Production License (0)

Display：

Package:46 kg/vacuum...Storage:store at RT Transportation:by sea/air Application:Suxibuzone

Verified-Platinum Supplier 1st Year Platinum
Supplier 370 Integral
370

Tel:+86-29-85733402

Address:No.108 ,west sector,south er huan,xi'an,china

615 Integral
615

Tel:86-29-85733402

Address:RM.11704 zizhu building, No. 108 west sector, south er huan, Xi'an China

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Metabolism of suxibuzone: Metabolism of suxibuzone. Esteve, J.; Roser, R.; Sagarra, R. (Dep. Invest., Lab. Dr. Esteve, S. A., Spain). Congr. Nac. Biofarm. Farmacocinet., [Actas], 1st, 497-500. Cons. Gen. Colegios Of. Farm.: Madrid, Spain. (Spanish) 1977. CODEN: 38SAAJ. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacodynamics) Phenylbutazone [50-33-9], oxyphenbutazone [129-20-4], and g-ketophenylbutazone [853-34-9] were detected in the urine of human subjects following treatment with suxibuzone (I) [27470-51-5]. I metab. in humans is evidently similar to that previously obsd. in mice and rats.

Pharmacokinetic study of suxibuzone in the rabbit: Pharmacokinetic study of suxibuzone in the rabbit. Esteve, J.; Roser, R.; Martinez, L.; Sagarra, R.; Salazar, R. (Cent. Invest. Lab., Dr. Esteve, S. A., Barcelona, Spain). Cienc. Ind. Farm., 9(10), 260-7 (Spanish) 1977. CODEN: CIDFA8. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) The pharmacokinetics of i.v. administered suxibuzone (I) [27470-51-5] (25 mg/kg) in rabbits could be represented by a bicompartmental model. I was rapidly distributed throughout the peripheral compartment and equil. concns. were reached in the organism within 10 min, probably as a result of the slow elimination of I. Values of pharmacokinetic parameters obtained after oral administration of I were representative of a monocompartmental model. At 1 h after i.p. injection of 50 mg I/kg, 82.5% of the drug was bound to serum proteins.